Sugi Predict

Sugi Predict / Compounds / SCHEMBL2380905

SCHEMBL2380905

SCHEMBL2380905

O=C1COc2c(Br)cccc2N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMYD3 Q9H7B4 1/20 0.45
▸ DRD2 P14416 3/20 0.41
▸ HTR1A P08908 3/20 0.41
▸ CCNB2 O95067 1/20 0.40
▸ CDK1 P06493 1/20 0.40
▸ CCNB1 P14635 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ CDK5 Q00535 1/20 0.40
▸ CDK5R1 Q15078 1/20 0.40
▸ CCNB3 Q8WWL7 1/20 0.40
▸ MMP12 P39900 1/20 0.40
▸ BRD4 O60885 3/20 0.40
▸ CREBBP Q92793 3/20 0.40
▸ PARP1 P09874 1/20 0.37
▸ PDE3B Q13370 1/20 0.37
▸ PDE3A Q14432 1/20 0.37
▸ AHR P35869 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29736794 1.00 SMYD3 (0.45) SMYD3DRD2HTR1ACCNB2CDK1
SCHEMBL22980312 0.84 HTR1A (0.40) SMYD3DRD2HTR1ABRD4CREBBP
SCHEMBL4484367 0.83 NPC1 (0.41) SMYD3HTR1ACCNB2CDK1CCNB1
SCHEMBL9050196 0.81 MMP12 (0.39) SMYD3CCNB2CDK1CCNB1GSK3B
SCHEMBL3590076 0.80 SMYD3 (0.46) SMYD3DRD2HTR1AMMP12BRD4
SCHEMBL4261663 0.79 IL4I1 (0.45) SMYD3DRD2HTR1ACCNB2CDK1
SCHEMBL22521052 0.79 SMYD3 (0.45) SMYD3DRD2HTR1AMMP12BRD4
SCHEMBL4317646 0.79 SMYD3 (0.51) SMYD3DRD2HTR1AMMP12BRD4
SCHEMBL1851941 0.79 CREBBP (0.58) SMYD3DRD2HTR1ACCNB2CDK1
SCHEMBL2599615 0.79 SMYD3 (0.45) SMYD3DRD2HTR1AMMP12BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235763-A1 FLUORESCENT PROBES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-13 — — WO disclosed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 — — US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 — — EP disclosed
WO-2025020886-A1 AZAQUINAZOLINE RING DERIVATIVE AND USE THEREOF 浙江星浩澎博医药有限公司 2025-01-30 — — WO disclosed
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors BEIGENE, LTD. (KY) 2025-01-23 — — US disclosed
US-20240189309-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2024-06-13 — — US disclosed
CN-118055930-A Thiadiazole derivative, composition and application thereof 北京丹擎医药科技有限公司 2024-05-17 — — CN disclosed
US-11919908-B2 Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2024-03-05 — — US disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
EP-1562918-B1 SUBSTITUTED BENZOXAZINONES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2008-01-16 — — EP disclosed
EP-1562918-B1 SUBSTITUTED BENZOXAZINONES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2008-01-16 — — EP disclosed
WO-2007134149-A2 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-22 — — WO disclosed
WO-2007134149-A2 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-22 — — WO disclosed
US-20070265252-A1 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-15 — — US disclosed
US-20070265252-A1 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-15 — — US disclosed
US-7141562-B2 Substituted benzoxazinones and uses thereof ROCHE PALO ALTO LLC (US) 2006-11-28 — — US disclosed
EP-1562918-A1 SUBSTITUTED BENZOXAZINONES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2005-08-17 — — EP disclosed
WO-2004041792-A1 SUBSTITUTED BENZOXAZINONES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2004-05-21 — — WO disclosed
US-20040092512-A1 Substituted benzoxazinones and uses thereof ROCHE PALO ALTO LLC 2004-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11919908-B2 Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors JAK2, JAK3, JAK1 SMYD3 2091/4885DRD2 1629/4885HTR1A 3818/4885
US-20240189309-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 SMYD3 1449/4885DRD2 4768/4885HTR1A 3903/4885
US-20070265252-A1 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS CETP, MTTP, CES1 SMYD3 2339/4885DRD2 4683/4885HTR1A 2926/4885
US-20040092512-A1 Substituted benzoxazinones and uses thereof CYP4X1, CYP3A5, CYP2D6 SMYD3 3189/4885DRD2 1395/4885HTR1A 986/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 SMYD3 3804/4885DRD2 4769/4885HTR1A 3498/4885
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors POLQ, POLK, POLI SMYD3 1262/4885DRD2 3959/4885HTR1A 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.